The latest developments across the GLP-1 landscape, from new drug approvals and clinical research to pricing changes and policy shifts. Stay informed on the updates that affect Ozempic, Wegovy, Mounjaro, and the wider category.
News & Updates
Novo Nordisk has filed a lawsuit against Eli Lilly, claiming the company runs deceptive advertising for its GLP-1 medications. For patients comparing semaglutide and tirzepatide options, this legal battle raises real questions about how drug makers market weight loss treatments and what you should actually trust when making a medication decision.
Novo Nordisk has filed a lawsuit against Eli Lilly, alleging the company ran misleading advertising around its GLP-1 medications. For patients comparing semaglutide and tirzepatide options, here is what this legal fight actually means for your treatment decisions and costs.
Millions of Americans who qualify for GLP-1 medications like semaglutide and tirzepatide are being turned away by their insurance plans due to high drug costs. This article breaks down why coverage gaps exist, what it costs to pay out of pocket, and the real options available to help you afford treatment.
Aspen Pharmacare has received Canadian approval to sell a generic version of semaglutide, the active ingredient in Ozempic, following Novo Nordisk's patent expiry in Canada. This marks a significant shift in the GLP-1 landscape that could eventually affect pricing and access across North America. Here is what patients and those considering GLP-1 therapy need to know.
GLP-1 retreats are emerging as a premium option for people on semaglutide or tirzepatide who want structured lifestyle coaching alongside their medication. But do they deliver results that justify the price tag? Here's what you need to know before booking one.
Novo Nordisk has launched a more affordable version of Ozempic in South Africa, raising questions about global GLP-1 pricing and what it could mean for patients in other markets. Here's a breakdown of the move and its broader implications for drug access and cost.
Major fast food chains are quietly restructuring their menus in response to the growing number of Americans on GLP-1 medications. For patients on semaglutide or tirzepatide, this cultural shift reflects a broader change in how the food industry views hunger, portion size, and appetite. Here's what it means for you.
Novo Nordisk has received its first European approval for an oral version of Wegovy, bringing a pill-based semaglutide option closer to reality for weight loss patients. This is a significant step beyond the current injectable format. Here's what it means for people considering or currently using GLP-1 medications.
